loader2
Login Open ICICI 3-in-1 Account

Orchid Pharma Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Orchid Pharma Ltd. 11 Nov 2025 15:47 PM

Q2FY26 Quarterly Result Announced for Orchid Pharma Ltd.

Pharmaceuticals company Orchid Pharma announced Q2FY26 results

  • Sales: Rs 194 crore against Rs 223 crore during Q2FY25, change -13%.
  • EBITDA: Rs 15 crore against Rs 38 crore during Q2FY25, change -61%.
  • PBT: Rs 2 crore against Rs 26 crore during Q2FY25, change -92%.
  • PAT: Rs 2 crore against Rs 26 crore during Q2FY25, change -92%.

Result PDF

Pharmaceuticals company Orchid Pharma announced H1FY25 results

H1FY25 Financial Highlights:

  • Sales reached Rs 222.7 crore, with EBITDA at Rs 37.5 crore.
  • Cumulative sales amounted to Rs 467.1 crore, a notable 22% YoY increase compared to H1FY24.
  • EBITDA for H1 rose to Rs 78.6 crore.

Manish Dhanuka, Managing Director, Orchid Pharma said: “Our growth is a testament to disciplined operational execution and the momentum from our strategic business development initiatives like the newly launched Orchid AMS. The positive trajectory is proof of our commitment to driving sustainable, profitable growth.”

Result PDF

Pharmaceuticals company Orchid Pharma announced FY24 results:

  • Sales for FY24 were at Rs 819.4 crore, up by 23% YoY.
  • PAT surged 71.60% YoY to Rs 94.7 crore in FY24.
  • A highlight of this quarter has been the progress of Orchid Pharma’s novel drug Enmetazobactam.

Speaking on the Q4 results, Manish Dhanuka, Managing Director, Orchid Pharma said, “Our revenues have experienced a significant increase over the past year. We have concentrated on maximizing capacity utilization while maintaining stringent cost controls. The positive outcomes of these initiatives, combined with a robust product pipeline and Capex of more than Rs 800 Crore over the next few years, indicate promising future prospects.”

Result PDF

Orchid Pharma announced Q2FY23 results:

  • Revenue jumps 36% QoQ and 36% YoY
  • EBITDA jumps 154% QoQ and 133% YoY

Manish Dhanuka, Managing Director, Orchid Pharma, said, “Our revenues have seen a sharp uptick over the past year. We have focussed on increasing capacity utilisations while controlling costs. Owing to all the measures we took, bearing fruit, and a strong product pipeline, the results are a sign of positive things to come."

 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app